Key result
TAVR performs similarly to SAVR for death or disabling stroke in intermediate-risk patients.
Why the study?
Does transcatheter aortic-valve replacement (TAVR) reduce death or disabling stroke in intermediate-risk patients compared to surgical aortic-valve replacement?
Does transcatheter aortic-valve replacement (TAVR) reduce death or disabling stroke in intermediate-risk patients compared to surgical aortic-valve replacement?
In intermediate-risk patients, TAVR provides similar outcomes to surgical aortic-valve replacement for the composite of death or disabling stroke.
Supports TAVR as alternative in intermediate-risk patients; extends evidence from high-risk cohorts.
In intermediate-risk patients, TAVR was similar to surgical aortic-valve replacement with respect to the primary end point of death or disabling stroke. (Funded by Edwards Lifesciences; PARTNER 2 ClinicalTrials.gov number, NCT01314313.).
No takes yet. Share an insight, caveat, or question.
Leon et al. (2016) studied this question. In intermediate-risk patients, transcatheter aortic valve replacement (TAVR) had outcomes similar to surgical aortic valve replacement regarding death or disabling stroke.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: